

Draft Agenda

MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP)

Centers for Disease Control and Prevention

Atlanta, Georgia 30329

Tuesday, April 15, 2025

8:00 Welcome & Introductions

Dr. Keipp Talbot (ACIP Chair)
Dr. Melinda Wharton (ACIP Executive Secretary, CDC)

8:15 Mpox Vaccine

Introduction

Presentation on immunogenicity and safety of JYNNEOS in 12-17 year olds

EtR for JYNNEOS in outbreaks and due to the 2022 global outbreak

Dr. Faisal Minhaj (CDC/NCEZID)

Dr. Buddy Creech (Vanderbilt)

Dr. Faisal Minhaj (CDC/NCEZID)

Dr. Grace Marx (CDC/NCEZID)

9:55 Lyme Disease Vaccine

10:00 Influenza Vaccines

Introduction

Influenza vaccine effectiveness update

FluMist for self or caregiver administration

Dr. Jamie Loehr (ACIP, WG Chair)

TBD

TBD

11:15

Break

11:30 COVID-19 Vaccines

Introduction

Moderna mRNA-1283 COVID-19 vaccine

Epidemiology and risk factors for COVID-19 hospitalizations

Vaccine effectiveness update

Workgroup considerations for use of 2025-2026 COVID-19 vaccines

Dr. Robert Schechter (ACIP, WG Chair)

Dr. Bishoy Rizkalla (Moderna)

Dr. Fiona Havers (CDC/NCIRD)

Dr. Ruth Link-Gelles (CDC/NCIRD)

Dr. Lakshmi Panagiotakopoulos (CDC/NCIRD)

1:30 Pneumococcal Vaccines

Workgroup Next Steps and Proposed Work Plan

Dr. Miwako Kobayashi (CDC/NCIRD)

1:45

Break

2:00 Human Papillomavirus (HPV) Vaccines

Introduction

Update on literature related to reduced number of doses for HPV vaccination series

KEN SHE study

HPV vaccination coverage

Modeling of reduced number of doses for HPV vaccination series

Modified EtR: wording of the age for routine HPV vaccination

Workgroup next steps

Dr. Oliver Brooks (ACIP, WG Chair)

Dr. Carla DeSisto (CDC/NCIRD)

Dr. Ruanne Barnabas (Harvard University)

Ms. Cassandra Pingali (CDC/NCIRD)

Dr. Jane Kim (Harvard University)

Dr. Ruth Stefanos (CDC/NCIRD)

Dr. Lauri Markowitz (CDC/NCIRD)

4:00 Cytomegalovirus (CMV) Vaccines

Introduction

CMV and cCMV epidemiology and disease burden

CMV vaccine safety and immunogenicity data

Initial workgroup considerations for CMV vaccine policy

Dr. Denise Jamieson (ACIP, WG Chair)

Dr. Tatiana Lanzieri (CDC/NCIRD)

Dr. Robert Paris (Moderna)

Dr. Tatiana Lanzieri (CDC/NCIRD)

Dr. David Sugarman (CDC/NCIRD)

5:00 Measles epidemiology and outbreaks

5:30 Adjourn

Draft Agenda

Wednesday, April 16, 2025

8:00 Welcome & Introductions

8:15 Meningococcal Vaccines

Introduction

GSK pentavalent vaccine: review of EtR and workgroup considerations

Updates to Meningococcal vaccines VFC resolution

Introduction to MenQuadfi label change for infants

MenQuadfi in infants: safety and immunogenicity

Workgroup considerations regarding MenQuadfi in infants

9:30

Break

9:45 Respiratory Syncytial Virus (RSV) Vaccines - Adults

Introduction

Manufacturer Presentation: mRNA-1345 (Moderna) Immunogenicity in Adults 18-59 at Increased Risk; 24-Month Re-Vaccination

Manufacturer Presentation: Arexvy (GSK) 36-Month Re-Vaccination

Economic Analysis of Adult RSV Vaccination, including benefits and risk discussion

Comparison of Economic Analyses of Adult RSV Vaccination

Evidence to Recommendations

Clinical Considerations

Dr. Keipp Talbot (ACIP Chair)

Dr. Jamie Loehr (ACIP, WG Chair)

Dr. Sarah Schillie (CDC/NCIRD)

Dr. Jeanne Santoli (CDC/NCIRD)

Dr. Sarah Schillie (CDC/NCIRD)

Dr. Rachel Dawson (Sanofi)

Dr. Sarah Schillie (CDC/NCIRD)

Dr. Albert Shaw (ACIP, WG Chair)

Dr. Frances Priddy (Moderna)

Dr. Susan Gerber (GSK)

Dr. Ismael Ortega-Sanchez (CDC/NCIRD)

Dr. Ismael Ortega-Sanchez (CDC/NCIRD)

Dr. Diya Surie (CDC/NCIRD), Dr. Michael Melgar

Dr. Michael Melgar (CDC/NCIRD)

12:15

Break

12:30 Chikungunya Vaccines

Introduction

Surveillance for adverse events following use of live attenuated chikungunya vaccine and its use among travelers

EtR for use of chikungunya vaccines among adolescent and adult travelers

EtR for use of virus-like particle chikungunya vaccine among laboratory workers

Clinical guidance for use of virus-like particle chikungunya vaccine among pregnant and breastfeeding women

Dr. Edwin Asturias (ACIP/WG Chair)

Dr. Susan Hills (CDC/NCEZID),

Dr. Erin Staples (CDC/NCEZID)

Dr. Susan Hills (CDC/NCEZID)

Dr. Erin Staples (CDC/NCEZID)

Dr. Susan Hills (CDC/NCEZID), Dr. Dana Meaney-Delman (CDC/NCBDDD)

3:00

Break

3:10 Public Comment

3:40 VOTES

Meningococcal Vaccines

Meningococcal Vaccines VFC

RSV Adult

Chikungunya Vaccines

Dr. Sarah Schillie (CDC/NCIRD)

Dr. Jeanne Santoli (CDC/NCIRD)

Dr. Michael Melgar (CDC/NCIRD)

Dr. Susan Hills (CDC/NCEZID)

4:10 Respiratory Syncytial Virus (RSV) Immunizations- Maternal/Pediatric

Introduction

EtR: Clesrovimab

Clinical considerations

Dr. Helen Chu (ACIP, WG Chair)

Ms. Danielle Moulia (CDC/NCIRD)

Dr. Jefferson Jones (CDC/NCIRD)

5:10 Adjourn

Draft Agenda

Acronyms

CDC	Centers for Disease Control and Prevention
CMS	Centers for Medicare and Medicaid Services
CORVD	Coronavirus and Other Respiratory Viruses Division
COVID-19	Coronavirus disease 2019
EtR	Evidence to Recommendations Framework
FDA	Food and Drug Administration
GRADE	Grading of Recommendations Assessment, Development and Evaluation
HRSA	Health Resources and Services Administration
HPV	Human papillomavirus
IHS	Indian Health Service
ISO	Immunization Safety Office
NCHHSTP	National Center for HIV, Hepatitis, STD and TB Prevention
NCIRD	National Center for Immunization & Respiratory Diseases
NCEZID	National Center for Emerging and Zoonotic Diseases
NIAID	National Institute of Allergy and Infectious Diseases
OIDP	Office of Infectious Disease and HIV/AIDS Policy
RSV	Respiratory Syncytial Virus (RSV)
SARS-CoV-2	Severe Acute Respiratory Syndrome Coronavirus 2
WG	Work Group
WHO	World Health Organization
VAERS	Vaccine Adverse Event Reporting System
VE	Vaccine Effectiveness
VFC	Vaccines for Children